Thursday, Benitec Biopharma Inc BNTC launched interim medical information from the 90-day timepoint following the administration of BB-301 to the research’s first topic (Topic 1) handled within the BB-301 Part 1b/2a research in Oculopharyngeal Muscular Dystrophy (OPMD).
“Up to now, no medical research have systematically demonstrated a medical enchancment in OPMD sufferers throughout each goal and subjective measures of swallowing. We’re, subsequently, happy to report optimistic interim medical information from a number of radiographic measures in addition to subject-reported consequence measures from the primary topic handled with BB-301,” stated Jerel Banks, Government Chairman and Chief Government Officer of Benitec.
Throughout the OPMD Pure Historical past Examine, which represents the pre-dose observational interval for every topic, Topic 1 skilled progressive worsening of dysphagia (issue swallowing) as demonstrated by the outcomes of the videofluoroscopic swallowing research (VFSS), the chilly water timed consuming check.
On the 90-day timepoint following the administration of BB-301, Topic 1 demonstrated enhancements in key videofluoroscopic assessments.
The outcomes of many assessments accomplished on the 90-day timepoint demonstrated enhancements over the preliminary measurements assessed on the topic’s first go to for the pure historical past observational research, which occurred greater than 12 months earlier than the 90-day evaluation.
Probably the most important VFSS enhancements at Day 90 had been noticed for swallowing duties centered on evaluating pharyngeal constrictor muscle perform and swallowing effectivity in consuming skinny liquids, strong meals, and thick, non-solid meals.
To this point, no extreme unwanted effects have been famous within the security profile of BB-301. Two topics skilled non permanent Grade 2 (gentle) Gastroesophageal Reflux Illness (GERD), which was handled with commonplace prescription medicine.
OPMD is a uncommon progressive muscle-wasting illness attributable to a poly(A)-binding protein nuclear 1 gene mutation. The illness is characterised by swallowing difficulties (dysphagia), limb weak spot, and eyelid drooping (ptosis). Dysphagia worsens over time.
Concurrently, Benitec Biopharma introduced a $40 million personal funding in public fairness (PIPE) financing from the sale of 5.7 million shares at $4.80/share and in lieu of shares of widespread inventory, pre-funded warrants to buy as much as an mixture of two.58 million shares at a value per pre-funded warrant of $4.7999, to sure institutional accredited buyers.
Value Motion: BNTC shares are up 24% at $5.95 on the final verify Thursday.
Illustration of Phrama lab employee created with MidJourney.
